AbbVie received a consensus rating of Buy . The company has an average rating score of 2.75 and is based on 12 buy ratings, 4 hold ratings and a sell rating. Is ABBV buying Zacks? Based on the size of the recent change in consensus estimate, along with three other factors related to earnings estimates, AbbVie has been assigned a Zacks Rank (Hold) . Therefore, while a company’s revenue growth is probably the best indicator of its financial health, if it can’t grow its revenue, not much is happening. What is AbbVie’s price target? Stock price forecasting The 20 analysts providing 12-month price forecasts for Abbvie Inc have an average target of 165.50, with a high estimate of 192.00 and a low estimate of 115.00 . Average estimate shows +2.08% increase from last price of 162.13. Plus.
what’s next for AbbVie?
The company is expecting a big year in 2022 , with continued Korea Phone Number Data revenue growth and hopes to generate tens of billions in free cash flow. The loss of Humira will reduce AbbVie’s sales in the near term, but other products could make up more of the difference. Is AbbVie a good buy right now? In short, AbbVie is a good stock to consider for both value and income investors . And even though the stock is at an all-time high, now is a good time to start a position.
Why is ABBV declining?
Shares of drugmaker AbbVie fell as much as 12.2% in intraday trading on Wednesday, closing up 7.1% after the US Food and Drug Administration said it found Austria Phone Number List that the use of a class of drugs known as JAK inhibitors , increases the risk of cancer, serious heart-related events and death . Which is better Abbott or AbbVie? AbbVie may be a better choice for those looking for value stocks. Therefore, for now – it is cheaper than its financials suggest. Abbott Labs, on the other hand, is more likely to see solid growth in the coming year, making it a better pick looking for short-term returns.
